Jomaa Pharma and Medicines for Malaria Venture (MMV) have signed a memorandum of understanding to jointly development a fosmidomycin-based treatment for acute Plasmodium falciparum-induced malaria.

The project has been initiated following the reports of the emergence of resistance to a commonly used anti-malaria drug artemisinin on the Thai-Cambodian border.

Jomaa Pharma is planning to begin a proof-of-concept study of fosmidomycin in combination with piperaquine later this year.

This will be followed by Phase II studies in children and toddlers in sub-Saharan Africa.

Jomaa Pharma is also partnering with the European and Developing Countries Clinical Trials Partnership to develop NACT products based on fosmidomycin under an existing grant.

Fosmidomycin is a molecule that possesses antimalarial and antibacterial activity.